anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
This study investigated the relationship between Metabolic Syndrome (MetS), sleep disorders, the consumption of some nutrients, and social development factors, focusing on gender differences in an unbalanced dataset from a Mexico City cohort. We used data balancing techniques like SMOTE and ADASYN after employing machine learning models like random forest and RPART to predict MetS. Random forest excelled, achieving significant, balanced accuracy, indicating its robustness in predicting MetS and achieving a balanced accuracy of approximately 87%. Key predictors for men included body mass index and family history of gout, while waist circumference and glucose levels were most significant for women. In relation to diet, sleep quality, and social development, metabolic syndrome in men was associated with high lactose and carbohydrate intake, educational lag, living with a partner without marrying, and lack of durable goods, whereas in women, best predictors in these dimensions include protein, fructose, and cholesterol intake, copper metabolites, snoring, sobbing, drowsiness, sanitary adequacy, and anxiety. These findings underscore the need for personalized approaches in managing MetS and point to a promising direction for future research into the interplay between social factors, sleep disorders, and metabolic health, which mainly depend on nutrient consumption by region.
Patients receive rituximab IV on days 1, 8, 15, and 22. A second treatment cycle is repeated at 3 months for a total of 8 doses of rituximab in the absence of progression of sclerosis or unacceptable toxicity.
768,291. Crushable tablets. SCHERING CORPORATION. Dec. 15, 1954 [Dec. 16, 1953], No. 36331/54. Class 81(1) A tablet comprises a matrix 11 of a crush-resistant material having embedded therein a number of hard pellets 12 of such number and size that the tablet which is resistant to breakage and chipping is capable of being crushed under thumb pressure. The tablet may contain from 30 to 70 per cent by weight of the spheroidal pellets of 10 to 16 mesh size which may be of different colours from that of the matrix, distributed in 70 to 30 per cent by weight of the comminuted matrix. Each pellet may comprise a core 13, composed of 65 parts sugar and 35 parts corn starch, and coated with a medicament 14 and covered with a protecting or entaric coating 15 which may vary in thickness and material to dissolve at different rates in the intestinal fluid to give a delayed or protracted effect. The tablet may contain two or more incompatible medicinal agents by dispersing one 'agent in the matrix and the other agents in or coated around the pellets, or by coating different pellets with different agents. Examples of incompatible substances are citric acid and sodium bicarbonate, aminophylline and ephedrine sulphate or antihistaminic salts e.g. 1 - parachlorophenyl - 1 - (2 - pyridyl)- 3 - dimethylamino - propane maleate, calcium creosotate and alkaloid salts, e.g. codeine phosphate, vitamin B 12  and reducing agents e.g. ascorbic acid, ferrano salts. Other medicaments which may be present are barbiturates, sulpha drugs, antihistamines, and analgesics e.g. aspirin, phenacetin. The coating materials mentioned are sugar, shellac, cellulose acetate and acetate-phthalate, and synthetic resins e.g. vinyl or urea resins. The matrix comprises known tablet excipients e.g. sugar, starch, and may also contain colouring materials.
Compounds, pharmaceutical compositions including the compounds, and methods of preparation and use thereof are disclosed. The compounds are triphenyl methane analogs. The compounds and compositions can be used to treat and/or prevent a wide variety of cancers, including drug resistant cancers, inflammatory, degenerative and vascular diseases, and parasitic infections. The compounds are triphenyl methane analogs of imipramine blue and analogs thereof, as defined herein. The compounds are believed to function by inhibiting tNOX expression, the effects of ROS, and/or the production of HIF2. Thus, the compounds are novel therapeutic agents for a variety of cancers and other diseases.
UNLABELLED: Currently available guidelines on the daily formula milk requirements of infants are based on the needs of infants with their growth pattern following the 50th percentile of the weight-for-age growth curve. Hence, current recommendations may not thoroughly detail the needs of infants across the broad spectrum of body weight percentiles. This study aimed to provide stratified recommendations for daily formula milk intake of fully formula-fed infants, across different weight-for-age categories from 0 to 4 months. At first, theoretical age- and gender-specific weight ranges were constructed for infants across five pre-defined weight-for-length percentile categories of the WHO growth standard. Thereafter, total daily energy requirements for each category were calculated and converted to daily formula milk needs. Subsequently, these stratified age- and weight-formula milk recommendations were compared to actual daily and relative formula milk of infants in these categories, retrieved from pooled individual infant formula milk intake data derived from 13 clinical intervention trials. A fitted regression model was used to evaluate differences in volume intakes across body weight categories as well as between theoretically derived and actual intake values. Median daily formula milk volume intake (ml/day) of infants differed significantly across the increasing weight-for-age categories at each time point, with significant differences between small and large infants. Interestingly, the relative daily formula milk volume intake (ml/kg/day) was higher for smaller infants compared to larger infants. The mean daily and relative formula milk intakes demonstrated the same pattern based on theoretical calculations as well as for the actual formula milk intake values retrieved from 13 pooled clinical intervention trials.
CONCLUSIONS: Based on theoretical calculations and actual formula intake data, we conclude that larger infants require a significantly higher daily formula milk intake than smaller infants, and we postulate that infants could benefit from more tailored formula milk intake recommendations.
WHAT IS KNOWN: • Adequate energy intake during the infancy period is crucial to support optimal growth and organ development, with the potential for long-lasting health effects. • Current available guidelines on the daily formula milk requirements of infants are based on the needs of infants with their growth pattern following the 50th percentile of the weight-for-age growth curve.
WHAT IS NEW: • Based on using both theoretical calculations and actual formula intake data, larger infants require a significantly higher daily formula milk intake than smaller infants. • Exclusive formula-fed infants could benefit from more tailored formula milk intake recommendations, in early infancy.
An infusion system includes an intravenous pole, a pump device, a power supply device, a computer processing device, and conduit. The intravenous pole includes a bottom portion adjacent a bottom end, an upper portion adjacent a top end, and a hollow shaft. The pump device is attached to the upper portion of the intravenous pole. The power supply device is attached to the bottom portion of the intravenous pole. The computer processing device is attached to the bottom portion of the intravenous pole. The conduit extends within the hollow shaft of the intravenous pole. The conduit connects the pump device, the power supply device, and the computer processing device.
At the Baseline Visit, following satisfaction of entry criteria and screening procedures, all subjects will be applying two products to their faces, each on one side only. The side of the face receiving each product is randomly assigned. One group will use Retin-A MICRO Gel, (tretinoin) 0.04% Pump on the left side of the face and Epiduo Gel (adapalene .1% and benzoyl peroxide 2.5%), on the right side of the face daily for 3 consecutive weeks after washing with study-supplied facial wash. The other group will use the same products, but on opposite sides of the face for three consecutive weeks after washing with the same study-supplied facial wash.

Subjects will return to the study center every weekday morning for evaluation and application of both study products. Applications done on the weekends, will be done at home by the subject. At each visit the subject will be scored for cutaneous treatment effects by a blinded evaluator. At baseline and at the end of each week, subjects will be photographed and have chromometer readings.
Dolutegravir (DTG)-based antiretroviral therapy (ART) is being scaled up as part of the preferred 1st-line ART regimen. However, DTG has recently been implicated as an obesogen that is associated with increased weight and adipose tissue gain compared to other antiretroviral agents. Obesity in pregnancy is associated with poor health outcomes for both mother and child as pregnancy is a critical period during which exposures leading to alterations in metabolic health may influence not only long-term maternal health but also fetal, neonatal, and ultimately child health. To address the gap of knowledge on the obesogenic effects of DTG in pregnant women living with HIV (WLHIV) and their children, this prospective cohort study will investigate the impact of DTG in pregnancy and its obesogenic effects on the metabolic health of WLHIV and their children, compared to women without HIV and their children. Up to 1900 pregnant women will be enrolled and followed to delivery and then as mother-infant pairs through 5 years postpartum (ORCHID study main cohort).

Additionally, a nested cohort study will be conducted and enroll a subset of 108 pregnant women who are currently being followed as part of the parent ORCHID study's main cohort. This substudy will explore the associations of DTG (initiating and continuing DTG use during pregnancy) with longitudinal perturbations in subcutaneous adipose tissue (SAT) function and changes in weight and adipose tissue mass in pregnancy through 2 years postpartum in WLHIV using a comparison group of HIV-seronegative women. They will been seen at up to 3 different time points (up to 2 visits during pregnancy and 1 visit postpartum) separate from the parent study to undergo a fat biopsy procedure to extract SAT samples.
Salsalate is insoluble in acid gastric fluids (<0.1 mg/ml at pH 1.0), but readily soluble in the small intestine where it is partially hydrolyzed to two molecules of salicylic acid. A significant portion of the parent compound is absorbed unchanged and undergoes rapid esterase hydrolysis in the body: its half-life is about one hour. About 13% is excreted through the kidneys as a glucuronide conjugate of the parent compound, the remainder as salicylic acid and its metabolites. Thus, the amount of salicylic acid available from salsalate is about 15% less than from aspirin, when the two drugs are administered on a salicylic acid molar equivalent basis (3.6 g salsalate/5 g aspirin). Salicylic acid biotransformation is saturated at anti-inflammatory doses of salsalate. Such capacity-limited biotransformation results in an increase in the half-life of salicylic acid from 3.5 to 16 or more hours. Thus, dosing with salsalate twice a day will satisfactorily maintain blood levels within the desired therapeutic range (10 to 30 mg/100 ml) throughout the 12-hour intervals. Therapeutic blood levels continue for up to 16 hours after the last dose. The parent compound does not show capacity-limited biotransformation, nor does it accumulate in the plasma on multiple dosing. Food slows the absorption of all salicylates including salsalate.

The mode of anti-inflammatory action of salsalate and other nonsteroidal anti-inflammatory drugs is not fully defined. Although salicylic acid (the primary metabolite of salsalate) is a weak inhibitor of prostaglandin synthesis in vitro, salsalate appears to selectively inhibit prostaglandin synthesis in vivo1, providing anti-inflammatory activity equivalent to aspirin2 and indomethacin3. Unlike aspirin, salsalate does not inhibit platelet aggregation4.

The usefulness of salicylic acid, the active in vivo product of salsalate, in the treatment of arthritic disorders has been established 5,6. In contrast to aspirin, salsalate causes no greater fecal gastrointestinal blood loss than placebo7.
Sorafenib 400 mg twice daily throughout the study. Patients will receive this as a single-agent for the first four weeks, then in combination with cisplatin followed by paclitaxel.
AIMS: Synovial sarcoma is a rare but aggressive variant of soft-tissue sarcoma. Literature is sparse and reported mostly from the West. We analysed the clinical profiles and prognostic factors of extremity synovial sarcoma patients in order to study their clinical journey.
MATERIALS AND METHODS: This was a retrospective analysis. All patients with extremity synovial sarcoma treated between 1992 and 2020 were included. Patients with metastases at presentation were excluded. A descriptive analysis of demographic and clinicopathological features of patients undergoing limb salvage surgery (LSS) or amputation was carried out. Overall survival and disease-free survival were calculated for the entire cohort as well as for the LSS and amputation groups. Factors prognostic for survival were identified.
RESULTS: In total, 157 patients had localised extremity synovial sarcoma. Predominantly, young adults (median 31 years) and males (61%) were affected. Over 70% of patients presented after recurrence or unplanned surgeries. Sixty-seven per cent of tumours were >5 cm, 69% were deep and 23% involved bone. The limb salvage rate was 64%. In the LSS group, adjuvant radiotherapy and chemotherapy were given to 72% and 68% of patients, respectively. In the amputation group, 72% of patients received adjuvant chemotherapy. In a median follow-up of 59 months, 39.4% of patients had recurrences, the majority (61.2%) were systemic. Five-year overall survival and disease-free survival were 53.4% and 49.8%, respectively. Overall survival was 63.9% and 29.7% in the LSS and amputation groups, respectively. On multivariate analysis, tumour size, depth, omission of radiotherapy and bone invasion were found to be the adverse prognostic factors.
CONCLUSION: This is one of the largest studies on extremity synovial sarcoma. Mostly males and young adults were affected. The limb salvage rate was 64%, despite most being referred after unplanned surgery. Almost 70% of patients received radiotherapy and chemotherapy. Overall survival was inferior in the amputation group. Tumour size >5 cm, depth and bone invasion were negative, whereas adjuvant radiotherapy was a positive prognostic factor for survival. Chemotherapy had no impact on survival.
<P>PROBLEM TO BE SOLVED: To provide a hydrogel base enough and together having required characteristics comprising high water retention, high adhesion, and high shape retention which are conventionally contrary to one another and capable of being prepared by a relatively simple production process, to provide a poultice base given by using the same, to provide a poultice, and to provide an aqueous gel sheet.  <P>SOLUTION: This hydrogel base is obtained by irradiating an aqueous solution of a polyacrylic acid derivative with energy rays, wherein the polyacrylic acid derivative has functional groups which are crosslinkable by the energy rays. The poultice base is prepared by making a medicament contained in the hydrogel base. The poultice is prepared by spreading the poultice base on a base material. The aqueous gel sheet is prepared by spreading the hydrogel base on a base material.  <P>COPYRIGHT: (C)2006,JPO&NCIPI
The most common signs to be expected are bradycardia, congestive heart failure, hypotension, bronchospasm and hypoglycemia. In cases of massive intentional overdosage (2-16 grams) of sotalol the following clinical findings were seen: hypotension, bradycardia, cardiac asystole, prolongation of QT interval, Torsade de Pointes, ventricular tachycardia, and premature ventricular complexes. If overdosage occurs, therapy with sotalol (AF) should be discontinued and the patient observed closely. Because of the lack of protein binding, hemodialysis is useful for reducing sotalol plasma concentrations. Patients should be carefully observed until QT intervals are normalized and the heart rate returns to levels >50 bpm. The occurrence of hypotension following an overdose may be associated with an initial slow drug elimination phase (half life of 30 hours) thought to be due to a temporary reduction of renal function caused by the hypotension. In addition, if required, the following therapeutic measures are suggested:
A non-smoker man in his second decade presented to a medical centre with intermittent haemoptysis over 2 years. The haemoptysis was infrequent initially to be ignored, but later, the episodes increased in amount and frequency. Routine blood tests including coagulation profile showed normal results. The chest radiography and echocardiography were normal. The contrast-enhanced CT scan of the chest showed a cystic lesion with intracystic abnormality and surrounding ground-glass opacity in the left upper lobe. The CT pulmonary angiography and invasive pulmonary angiography showed the abnormality to be a dilated pulmonary vessel draining into the left atrium, thereby confirming the diagnosis of congenital pulmonary varix contained within a lung cyst. The patient underwent a successful lobectomy following which he experienced no further haemoptysis.
OBJECTIVES: To evaluate the efficiency and tolerability of pericapsular nerve group block (PENG) for the treatment of chronic hip pain.
METHODS: This is a retrospective, single-centre, 4-group study conducted over a 3-month period to find out the most typical cause of chronic hip pain. A total of 112 patients with symptomatic hip osteoarthritis (OA), Stage 2-3, greater trochanteric pain (GTPS) and chronic pain after total hip arthroplasty (cTHA), who had an ultrasound-guided PENG block, were selected. To assess the effectiveness of the treatment, the Western Ontario and McMaster Universities osteoarthritis index (WOMAC) and visual analogue scale (VAS) scores of the patients prior to treatment were compared with their scores after the 1st week, 1st month, and 3rd month of treatment. The study also aimed to analyse the patients' initial feelings of alleviation following the block (1st VAS/2) and problems experienced both during and after the block.
RESULTS: The parameters studied included pain, stiffness, and results of physical activity in the 1st week, 1st month, and 3rd month following PENG block application. At the beginning of the 1st week, of the 112 patients who were administered a PENG block for hip pain, we reported a 62% improvement in pain, a 52% reduction in stiffness, and a 53% increase in physical activity. Even though these results slightly declined in the 1st and 3rd months, the rates were still higher than 45%.
CONCLUSIONS: Overall, the PENG block was well-tolerated by the patients in our study. No treatment-related infections or any other serious complications were observed.
The invention belongs to the field of digital medical treatment, and particularly relates to a chronic obstructive pulmonary disease identification system constructed based on digitized lung sounds, a construction method and application thereof. The system comprises a data acquisition module, a preprocessing module, a conversion module, a data processing module, a data enhancement training module, a deep learning module, an identification module, a grading module and a display module. And collecting the digital lung sound records of the candidates, converting the digital lung sound records into Mel spectrogram, and diagnosing by using a deep neural network. The candidates are COPD patients, healthy or suffering from other lung diseases, and the disease class of COPD patients will be given by the device on board the identification system. The examination only requires lung auscultation of lung sounds collected in a clinical or other setting, reducing the risk of radiation injury and possible contact infection during routine diagnosis. When the new coronary pneumonia is epidemic, a scheme is provided for early diagnosis of COPD while the infection risk is reduced, and the diagnosis efficiency of respiratory medicine, particularly COPD diseases, is improved.
An isolated polypeptide includes the amino acid sequence shown in SEQ. ID No. 13 and an isolated nucleic acid encoding the polypeptide, such as an isolated nucleic acid including the nucleic acid sequence shown in SEQ. ID No. 17. The isolated polypeptide includes two heparin binding polypeptides connected in tandem and the isolated nucleic acid encodes these. The polypeptide and nucleic acid sequences can improve retroviral vector mediated gene transfer efficiency into target cells.
NEW MATERIAL:Compounds of formula I (R<2> is lower alkyl; Het is lower alkyl substituted tetrazolyl or tetrazolopyridazinyl). EXAMPLE:1-Methyltetrazol-5-yl 4-ethyl-2,3-dioxopiperazin-1-ylcarbonyl thiolate. USE:An active acylating agent. Used for production of a kind of antibacterial agent (cephalosporin). PREPARATION:4-Ethyi-2,3-dioxopiperazinylcarbonyl chloride of formula 4 is reacted with 1-methyltetrazole-5-thiol of formula 5a to obtain an objective compound of formula 2. The yield is improved by carrying out the reaction using a novel tri-n-butyltin thiolate of formula 5b.
Neospot is a 5-in-1 wearable vitals measurement device designed to measure temperature, blood pressure, pulse rate, respiratory rate and blood oxygen saturation. For the standard of care vitals measurement, conventional vital signs will be measured using mercury blood pressure cuffs and infrared or mercury thermometers for blood pressure and temperature respectively, pulse oximeter for oxygen saturation and a 1-minute count of heart rate and breathing rate.
PROBLEM TO BE SOLVED: To obtain a paste-like common salt free from separation of water and useful as a massaging agent by combinedly using agar and a specific cellulose as thickeners and including an inorganic salt such as NaCl in a definite amount or above. SOLUTION: Sodium chloride is combined with at least one kind of material selected from a group of agar, carboxymethyl cellulose sodium and fibrous cellulose and water. Further, at least one kind of material selected from a group comprising a calcium salt, a magnesium salt and a potassium salt and/or glycerin may be added to the system. A blend ratio of each component of the paste-like massaging agent is shown in the following each amount: NaCl, >140wt.%; agar, 1.0-2.3wt.%; carboxymethyl cellulose sodium, 0.1-1.0wt.%; fibrous cellulose, 2.5-3.5wt.%; water, about 60wt.%. When total amount of each component is 100 pts.wt., an amount of a salt selected from a group of Ca salt, Mg salt and K salt is 1-20 pts.wt. and an amount of glycerin I is about 5-20 pts.wt.